Skip to main content
H.R. 5882 116th Congress House

GENE Therapy Payment Act

Official title: To amend title XIX of the Social Security Act to provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sha… Show full official titleShow less

Official title: To amend title XIX of the Social Security Act to provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements, and for other purposes.

Introduced: February 12, 2020 See on congress.gov
Health Administrative law and regulatory proceduresAppropriationsCongressional oversightDepartment of Health and Human Services
More subjectsShow fewer subjects
Drug safety, medical device, and laboratory regulationDrug therapyGeneticsGovernment studies and investigationsHealth care costs and insuranceHome and outpatient careIntergovernmental relationsManufacturingMedicaidPrescription drugsState and local government operations
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 12, 2020
Referred to the House Committee on Energy and Commerce.
Feb 12, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 12, 2020

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act

This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.

 Related & companion bills 3
  • HR 19 Lower Costs, More Cures Act of 2019
  • S 2543 Prescription Drug Pricing Reduction Act of 2019
  • S 4199 Prescription Drug Pricing Reduction Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 5
All 5 Democratic 2 Republican 3
D
Bera, Ami
California · Feb 12, 2020
 D
Crow, Jason
Colorado · Feb 12, 2020
 R
Kelly, Mike
Pennsylvania · Feb 12, 2020
 R
Marshall, Roger
Kansas · Feb 12, 2020
 R
Schweikert, David
Arizona · Feb 12, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5882: GENE Therapy Payment Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-5882/
MLA
"H.R. 5882: GENE Therapy Payment Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-5882/.
Bluebook (legal)
H.R. 5882, 116th Cong. (2026), https://openamerica.io/bill/116-HR-5882/.
Markdown link
[H.R. 5882: GENE Therapy Payment Act](https://openamerica.io/bill/116-HR-5882/)
Report a problem